New Medtronic VP, GM for TAVR, Congenital Jorie Soskin. [Image from Nina Goodheart on LinkedIn]Medtronic

新美敦力副总裁，TAVR总经理，先天性Jorie Soskin。[来自LinkedIn上Nina Goodheart的图片]美敦力

(NYSE: MDT)

（纽约证券交易所：MDT）

+

+

has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

。

Soskin’s LinkedIn page now lists his position as VP and GM for Structural Heart at the medtech giant. Nina Goodheart, SVP and president of Structural Heart and Aortic at Medtronic, shared the news of Soskin’s appointment on LinkedIn.

Soskin的LinkedIn页面现在列出了他在这家医疗科技巨头担任Structural Heart副总裁和总经理的职位。美敦力高级副总裁兼结构性心脏和主动脉总裁尼娜·古德哈特（NinaGoodheart）在LinkedIn上分享了Soskin被任命的消息。

“Big news from our Structural Heart & Aortic team at Medtronic — Jorie Soskin has joined us as vice president and general manager of our TAVR and Congenital businesses,” Goodheart wrote. “His commitment to improving patient outcomes and raising the standard for care are welcome additions to our team and he’s already diving in meeting with our Medtronic team and physician partners across the globe.”.

古德哈特写道：“美敦力结构性心脏与主动脉团队的重大消息——乔丽·索斯金加入我们，担任TAVR和先天性业务的副总裁兼总经理。”。。

Soskin joined Medtronic through the company’s acquisition of CoreValve in 2009. The company’s current TAVR (transcatheter aortic valve replacement) offerings still bear the CoreValve name.

Soskin于2009年通过美敦力收购CoreValve加入美敦力。该公司目前的TAVR（经导管主动脉瓣置换术）产品仍以CoreValve的名称命名。

He has more than 15 years of experience within the cardiovascular space at Medtronic since that acquisition. Goodheart said he brings a “drive for innovation and strong track record of improving patient outcomes and access through focused execution of strategic business opportunities.

自收购以来，他在美敦力心血管领域拥有超过15年的经验。古德哈特说，他带来了“创新的动力，以及通过集中执行战略商业机会来改善患者结果和获得机会的良好记录。

“I look forward to working alongside Jorie as he propels innovative excellence within our team,” Goodheart said.

古德哈特说：“我期待着与乔丽一起工作，因为他推动了我们团队的创新卓越。”。